[3-hydroxy-2-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]decanoyl] 3-hydroxy-2-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]decanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [3-hydroxy-2-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]decanoyl] 3-hydroxy-2-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]decanoate
• 化学式: C₃₂H₅₈O₁₃
• 分子量: 650.8
• InChiKey: PIBDXTZZGDSHPP-JWLPLXHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  45
• 可旋转键数：
  20
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  224
• 氢给体数：
  8
• 氢受体数：
  13

文献信息

• Production of dirhamnose-lipid in recombinant nonpathogenic bacterium Pseudomonas chlororaphis
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE

  公开号：US10190144B2

  公开（公告）日：2019-01-29

  Pseudomonas chlororaphis NRRL B-30761 produces monorhamnolipids with predominantly 3-hydroxydodecenoyl-3-hydroxydecanoate (C12:1-C10) or 3-hydroxydodecanoyl-3-hydroxydecanoate (C12-C10) as the lipid moiety under static growth conditions. The cloning and sequencing of three genes and proteins involved in the biosynthesis of monorhamnose-lipid (R1L) is described. Expression of two of these genes, i.e., rhlA and rhlB, together in P. chlororaphis NRRL B-30761 increases R1L production by at least 10-fold. Also the generation of a recombinant P. chlororaphis NRRL B-30761 capable of synthesizing dirhamnose-lipid (R2L) is described. Characterization of R1L and R2L produced by the recombinant P. chlororaphis NRRL B-30761 is also described.

  在静态生长条件下，绿假单胞菌（Pseudomonas chlororaphis）NRRL B-30761 产生的单鼠李糖脂主要以 3-hydroxydodecenoyl-3-hydroxydecanoate (C12:1-C10) 或 3-hydroxydodecanoyl-3-hydroxydecanoate (C12-C10) 为脂质分子。本文介绍了参与单鼠李糖脂（R1L）生物合成的三个基因和蛋白质的克隆和测序。在 P. chlororaphis NRRL B-30761 中同时表达其中的两个基因，即 rhlA 和 rhlB，可使 R1L 的产量增加至少 10 倍。此外，还描述了能够合成地尔汉糖脂质（R2L）的重组 P. chlororaphis NRRL B-30761 的产生过程。还描述了重组 P. chlororaphis NRRL B-30761 产生的 R1L 和 R2L 的特征。
• METHOD FOR TREATING LOCALIZED FAT DEPOSITS
  申请人：Rhamnopharma Inc.

  公开号：US20150051162A1

  公开（公告）日：2015-02-19

  The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.
• PRODUCTION OF DIRHAMNOSE-LIPID IN RECOMBINANT NONPATHOGENIC BACTERIUM PSEUDOMONAS CHLORORAPHIS
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE

  公开号：US20160102330A1

  公开（公告）日：2016-04-14

  Pseudomonas chlororaphis NRRL B-30761 produces monorhamnolipids with predominantly 3-hydroxydodecenoyl-3-hydroxydecanoate (C 12:1 -C 10 ) or 3-hydroxydodecanoyl-3-hydroxydecanoate (C 12 -C 10 ) as the lipid moiety under static growth conditions. The cloning and sequencing of three genes and proteins involved in the biosynthesis of monorhamnose-lipid (R 1 L) is described. Expression of two of these genes, i.e., rhlA and rhlB, together in P. chlororaphis NRRL B-30761 increases R 1 L production by at least 10-fold. Also the generation of a recombinant P. chlororaphis NRRL B-30761 capable of synthesizing dirhamnose-lipid (R 2 L) is described. Characterization of R 1 L and R 2 L produced by the recombinant P. chlororaphis NRRL B-30761 is also described.
• METHOD FOR TREATING DUPUYTREN'S DISEASE
  申请人：Dale Biotech, LLC

  公开号：US20220088047A1

  公开（公告）日：2022-03-24

  The present invention is directed to methods for treating Dupuytren's disease, osteoarthritis, and adhesive capsulitis. The method comprises the steps of identifying a subject in need thereof, and administering to the subject an effective amount of one or more rhamnolipids, optionally in combination with niclosamide. A pharmaceutical composition comprising rhamnolipids, optionally in combination with niclosamide or a salt thereof, can be applied by any accepted mode of administration including oral, topical, or injection within or around the affected body part such as an affected hand, knee, or shoulder.
• US8765694B2
  申请人：——

  公开号：US8765694B2

  公开（公告）日：2014-07-01